---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-040847"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2024-03-29T23:59:59+00:00"
generated_at: "2026-06-04T05:26:58.937722+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kiniksa proposes redomicile from Bermuda to UK via scheme of arrangement; expects completion H2 2024

## Summary
- Proposes to change principal holding company incorporation from Bermuda to the UK by scheme of arrangement.
- Shares exchanged 1:1 for new UK company shares; continues trading on Nasdaq under ticker KNSA.
- Cites improved tax treaty access and protection from OECD/Bermuda tax initiatives as key reasons.
- No material impact on financial results expected; completion targeted for second half 2024.
- Convening hearing before Bermuda Supreme Court set for April 19, 2024.

## SEC filing metadata
- accession: 0001104659-24-040847
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2024-03-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000110465924040847/0001104659-24-040847-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000110465924040847/tm249997d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-040847
- JSON: https://secwatch.observer/filing/0001104659-24-040847.json
- Plain text: https://secwatch.observer/filing/0001104659-24-040847.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.